Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency

Trial Profile

A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HMI-102 (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms pheNIX
  • Sponsors Homology Medicines
  • Most Recent Events

    • 27 Jun 2019 According to a Homology Medicines media release, Steve Glyman, M.D., Vice President of Clinical Development, and his team have been working with Boston Childrens Hospital and Icahn School of Medicine at Mount Sinai to enroll patients with the goal of bringing additional trial sites on board this year.
    • 06 Jun 2019 Status changed from not yet recruiting to recruiting.
    • 20 May 2019 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top